109P Patient-reported outcomes with acasunlimab monotherapy and in combination with pembrolizumab: Results from a phase II study of PD-L1+ mNSCLC
Acasunlimab (ACA, DuoBody®-PD-L1x4-1BB) monotherapy and in combination with pembrolizumab (PEM; Q3W/Q6W) was evaluated in a Ph 2 trial of patients (pts) with PD-L1+ mNSCLC who progressed after ≥1 prior SOC treatment including PD-L1 inhibitors (NCT05117242). ACA+PEM Q6W showed promising OS, durable benefit, and a manageable safety profile. Exploratory analyses were conducted to assess patient-reported outcomes (PROs) and HRQoL from primary analysis of the Ph 2 trial at data cutoff (12/02/2024).
Authors
- Yanhong Zhou (ORCID: https://orcid.org/0000-0003-2744-2100)
- Willemijn S.M.E. Theelen (ORCID: https://orcid.org/0000-0001-9772-0511)
- Gilles Quéré (ORCID: https://orcid.org/0000-0001-5920-0662)
- Vijay N. Joish (ORCID: https://orcid.org/0000-0002-7422-6809)
- J.G. Aerts
- A. Chekalova
- S. Gadgeel
- M. Holst Mørch
- B. Besse
- M.J. Chisamore
- D.M. Kowalski
- X. Zhou
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Genmab (United States) (US)
- Institut Gustave Roussy (FR)
- Erasmus MC (NL)
- Henry Ford Hospital (US)
- RTI Health Solutions (US)
- Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NL)
- Centre Hospitalier Régional Universitaire de Brest (FR)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106416
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00